TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Co Enzyme Q10 as Adjuvant Therapy to Letrozole on Spermiogram

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male patients.~2. Aged 18 - 60 years.~3. Confirmed diagnosis with idiopathic Oligo-Astheno-Teratozoospermia (iOAT) syndrome.~Exclusion Criteria:~1. Patients who have been found to have additional infertility causes, such as varicocele or Obstruction of the ejaculatory duct.~2. Those who have had surgery for male factor infertility.~3. Patients with infections such as STD.~4. Patient with renal or liver disease~5. Incomplete patient data

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: SHAM_COMPARATOR): group A (29) patients received letrozole 2.5mg twice weekly for 3 months
- Group B (Type: EXPERIMENTAL): Group B (38) patients receive letrozole 2.5mg twice a week plus Co Q10 400 mg per day for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Genetically confirmed variant in the tissue-nonspecific isozyme alkaline phosphatase (ALPL)-Gene.~* Clinical symptoms of HPP.~* Medical history with 1) at least two independent measures of Alkaline Phosphatase (ALP) below lower level of normal (LLN) and 2) at least one measurement of either PPi or PLP above upper level of normal (ULN).~* Provision of signed and dated informed consent form (ICF) in accordance with local regulations at screening.~* Patients must agree not to get pregnant/not to get their partner pregnant, during the trial. Consequently, patients must agree to use adequate contraception as detailed in study protocol.~Exclusion Criteria:~* Participant is unable or unwilling to participate in all scheduled visits and perform all protocol-mandated assessments.~* Has a known or suspected hypersensitivity to ilofotase alfa or any components of the formulation used.~* Body weight \< 40 kilogram and \> 120 kilogram.~* Patient has a history of clinically significant abnormalities or of any illness that, in the opinion of the trial investigator, might confound the results of the trial or pose an additional risk to the patient by their participation in the trial.~* NSAID use in the past 2 weeks.~* Use of corticosteroids in the past 4 weeks.~* Use of compounds intended to interfere with bone metabolism (e.g. Denosumab, Teriparatide, Romosozumab, Raloxifene) in the past 3 months.~* Use of bisphosphonates in the past 2 years.~* Participation in a drug trial within 60 days, or five times the half-life of the drug, whichever is longer, prior to administration of ilofotase alfa.~* Use of asfotase alfa in the previous 3 months. Patients will not be withheld from approved asfotase alfa if medically indicated.~* A patient who is currently pregnant or lactating.~* Use of supplements including Vitamin B6.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 0.8 mg/kg ilofotase alfa (Type: EXPERIMENTAL): Single dose administered intravenously over 1 hour
- 3.2 mg/kg ilofotase alfa (Type: EXPERIMENTAL): Single dose administered intravenously over 1 hour

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with 5 to 20 clinically typical, visible and discrete AKs within a treatment area of sun-damaged skin on the full balding scalp (the balding part of the scalp should be greater than 25 cm2 (4 in2) and up to approximately 250 cm2 (40 In2)~* Subjects with minimum 3 clinically typical, visible and discrete AKs within a tracking area of 50 cm2 (8 In2). The tracking area must be within the treatment area~Exclusion Criteria:~* Location of the treatment area (balding scalp) within 5 cm of an incompletely healed wound or within 5 cm of a suspected BCC or SCC~* Treatment with ingenol mebutate gel in the treatment area within the last 12 months~* Lesions in the treatment area that have: atypical clinical appearance (e.g. hyperthrophic, hyperkeratotic or cutaneous horns) and /or, recalcitrant disease (e.g. did not respond to cryotherapy on two previous occasions)~* History or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication (e.g. eczema, unstable psoriasis, xeroderma pigmentosum)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 43204 gel (Type: EXPERIMENTAL): Treatment once daily for 3 days
- Vehicle gel (Type: PLACEBO_COMPARATOR): Treatment once daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Vaccine Response in Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+ thalassemia, HbS/Other)~2. Has not received any COVID-19 vaccination prior to enrollment~3. Scheduled for a COVID-19 vaccination (type does not matter) as part of routine clinical care~4. Willing and able to sign consent~Exclusion Criteria:~1. Unwilling to have labs drawn or complete study requirements.~2. Previous therapy curative of SCD (including bone marrow transplant and gene therapy)~3. Previous receipt of anti-COVID-19 antibody therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational Cohort (Type: None): Previously unvaccinated persons with sickle cell disease who are scheduled to receive their initial COVID-19 vaccine series.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Periodontitis in Menopausal Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients diagnosed as; periodontitis patients~* presence of a minimum of 6 teeth in the mouth~* at least 3 periodontal sites with probing pocket depth more or equal to 5mm~* women experiencing menopause for at least a year~Exclusion Criteria:~* women suffering from any systemic disorder that might affect the periodontal tissues such as; Diabetes Mellitus, immune disorders,..~* anemic patients~* smokers~* patients taking NSAIDs, supplements, antibiotics regularly used mouthwashes within the last 3 months~* participants in any other clinical trials

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- group 2 polyunsaturated fatty acids (Type: EXPERIMENTAL): intervention: systemic administration of 1000 mg polyunsaturated fatty acids. to be taken once daily with meals for 12 months~patients treated by scaling and root planing and oral systemic administration of Omega-3 fatty acids a soft gelatinous capsule containing 1000 mg polyunsaturated fatty acids (PUFAs)
- group 1 control (Type: SHAM_COMPARATOR): control group, patients treated by scaling and root planing and an oral soft gelatinous capsule containing olive oil to be taken once daily with meals for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient Is Diagnosed With Asthma For At Least 6 Months~* Patient's Peak Expiratory Flow (PEF) Is 80% Of Predicted Value (Appendix 10)~* Patient Is Currently Untreated, Or Patient Is A User Of Short-Acting 2-Agonist On An As-Needed Basis, Or Patient Is A User Of Ics At Any Dosage~* Physician And/Or Patient Are Dissatisfied With Current Controller Therapy, Or Patient Is Reluctant To Take Ics Therapy, Or Patient Is Insufficiently Controlled Due To Non-Adherence With Current Therapy Through The Preceding 6 Weeks~Exclusion Criteria:~* As Per Canadian Guidelines, Patient Is On A Laba Alone (Formoterol (Oxeze), Salmeterol (Serevent)) Or A Combination Product (Advair Or Symbicort)~* Patient Is Well Controlled, Adherent And Satisfied With Current Controller Therapy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women age 21 years or older~* Taking on average 5.0 mg/day prednisone or equivalent for at least 3 months prior to screening~Exclusion Criteria:~* Taking bisphosphonates within past 6 months~* More than 30 micrograms/day of estradiol or equivalent in past 3 months~* History of alcoholism or drug abuse in past year~* Pregnant women or nursing mothers

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Teriparatide 20 micrograms/day injection plus oral placebo, 36 months
- B (Type: ACTIVE_COMPARATOR): Alendronate 10 mg/day oral plus injection placebo, 36 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese males and females aged 20 or above who have signed the informed consent form~* The patient has alcohol dependence, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) and confirmed by Mini-international Neuropsychiatric Interview (M. I. N. I.)~* The patient has a drinking risk level of High or above (\> 60 g for men and \> 40 g for women) both at the Screening Visit and at the Randomization Visit .~Exclusion Criteria:~* The patient with a current diagnosis or history of substance use disorders (except for alcohol, nicotine, and caffeine), according to DSM-IV-TR and confirmed by M. I. N. I.~* The patient has reported current use of, or has tested positive for, drugs of abuse (opiates, methadone, cocaine, amphetamines, barbiturates) at the screening test

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nalmefene hydrochloride 10 mg (Type: EXPERIMENTAL): None
- Nalmefene hydrochloride 20 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female age \> 18 years~2. Invasive breast cancer ≤ 5 cm, unifocal bifocal or multifocal~3. Diagnosis confirmed by biopsy~4. Breast cancer extended in situ~5. First surgical treatment~Exclusion Criteria:~1. Neoadjuvant chemotherapy or hormone therapy.~2. Multicentric tumor~3. Pregnant patient~4. Ongoing participation in another clinical trial with an investigational drug

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infracyanine (Type: EXPERIMENTAL): In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Fampridine-SR in Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a confirmed diagnosis of multiple sclerosis~* Are able to walk with or without an assistive device~Exclusion Criteria:~* Pregnancy, breastfeeding or females of childbearing potential not using adequate birth control~* Participating in other investigational drug trials~* A medical history or clinical findings that preclude entry into the study~* A medication history that precludes entry into the study~* Previously treated with 4-aminopyridine (4-AP)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo- sugar pill (Type: PLACEBO_COMPARATOR): Placebo control
- Fampridine-SR (Type: EXPERIMENTAL): 10 milligram (mg) tablet b.i.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the surgical intensive care unit at The Methodist Hospital (Houston, TX)~* Anticipated surgical intensive care unit length of stay of 48 hours or more~Exclusion Criteria:~* Pregnancy~* Age less than 18 years old~* Braden score of less than 9 upon admission to the surgical intensive care unit~* Known allergy to chlorhexidine gluconate~* Active skin irritation upon admission to the surgical intensive care unit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chlorhexidine gluconate bathing (Type: ACTIVE_COMPARATOR): Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
- Standard bathing (Type: PLACEBO_COMPARATOR): Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women or men within an age range from 30 to 69 years with uncomplicated hypertension.~* Blood pressure measured in the sitting position after at least 5 minutes rest (average of three readings at the last run-in-visit) should range from 140 to 179 mm Hg systolic or from 90 to 109 mm Hg diastolic (grades 1 or 2 of hypertension). Patients must have uncomplicated hypertension with a maximum of two additional risk factors, as defined in the 2007 guidelines of the European Societies of Hypertension and Cardiology.~* Systolic blood pressure in the upright position must be at least 110 mm Hg (mean of three readings obtained immediately after the patient has assumed a standing position).~* Patients who have never been treated for hypertension or in whom previous antihypertensive drug treatment has been discontinued for at least four weeks before the last run-in visit can be randomised. If two weeks after discontinuation of previous antihypertensive treatment the blood pressure is higher than 160 mm Hg systolic or higher than 100 mm Hg diastolic and if the patient has complaints, the patient can be randomised immediately to active blood pressure lowering treatment with either the newer or older antihypertensive drugs.~* The patient must provide informed written consent.~Exclusion Criteria:~* Premenopausal women not applying anticonception.~* A history of cardiovascular disease.~* Secondary hypertension.~* Electrocardiographic left ventricular hypertrophy.~* More than two cardiovascular risk factors in addition to hypertension.~* Diabetes mellitus.~* Renal dysfunction.~* Recent treatment with two or more antihypertensive drugs or a contra-indication to discontinue blood pressure lowering agents for 4 weeks.~* Severe non-cardiovascular disease.~* Known contra indications for the first-line study medications.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- amlodipine plus valsartan (Type: EXPERIMENTAL): In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.
- hydrochlorothiazide plus bisoprolol (Type: ACTIVE_COMPARATOR): In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred for contrast enhanced MRI of the CNS based on symptoms or previous procedures.~Exclusion Criteria:~* Patients with acute renal insufficiency~* Patients with severe renal disease~* Patients with any contraindication to magnetic resonance imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gadobutrol (Gadavist, BAY86-4875) (Type: EXPERIMENTAL): Participants were administered a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) bolus administration using a power injector via a peripheral vein (an antecubital vein was preferred). Gadobutrol was injected at a rate of 2 mL/second followed by a 20-mL 0.9% saline flush at the same rate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of chylomicronemia~* A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia)~* Fasting triglycerides (TG) ≥ 750 mg/dL (8.4 mmol/L) at Screening~Exclusion Criteria:~* Diabetes mellitus if newly diagnosed or if HbA1c ≥ 9.0%~* Other types of severe hypertriglyceridemia~* Active pancreatitis within 4 weeks of screening~* Acute Coronary Syndrome within 6 months of screening~* Major surgery within 3 months of screening~* Treatment with Glybera therapy within 2 years of screening~* Previous treatment with IONIS-APOCIIIRx~* Have any other conditions in the opinion of the investigator which could interfere with the participant participating in or completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks.
- Volanesorsen (Type: EXPERIMENTAL): Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete